Carmat Heart Sale in 2-5 Years, CEO Tells France Info

(Corrects Cadudal’s title in first paragraph in story published yesterday.)

Carmat (ALCAR) SAS, whose artificial heart was implanted in a patient for the first time last month, sees the commercialization of the device in “two-to-five years,” Chairman Jean-Claude Cadudal said in an interview on France Info Radio.

The patient who got the implant on Dec. 18 is “doing as well as is possible,” after an operation “of such gravity,” Cadudal told the radio station.

Three more such implants are planned in France, the executive said.

He said the four implants would be the basis for seeking certification for the device in Europe to allow it to be sold commercially. The company would need similar approvals in the U.S., he said.

To contact the reporter on this story: Vidya Root in Paris at vroot@bloomberg.net

To contact the editor responsible for this story: Vidya Root at vroot@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.